Use of Anti-CD146 Autoantibodies for the Diagnosis of Pulmonary Diseases Secondary to Occupational Exposure to Silica (CD146-SILICE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria for non-exposed group:
- Subject, male or female, aged 18 or over
- Subject with low exposure to silica <0.1 mg/m3 in the course of their professional activity, quantified during an occupational health consultation using an employment-exposure matrix
- Subjects capable of consenting to participate in the study by signing a written informed consent form
- Subjects who are beneficiaries of or affiliated with a social security system
Inclusion Criteria for exposed group:
- Subject, male or female, aged 18 or over
- Subject with moderate or high exposure to silica (>= 0.1 mg/m3) in the course of their professional activity, quantified during an occupational health consultation using an employment-exposure matrix.
- Subjects capable of consenting to participate in the study by signing a written informed consent form
- Subjects who are beneficiaries of or affiliated with a social security system
Exclusion Criteria for each group:
- Minor subject
- Subject refusing to undergo the examinations required by the protocol
- Contraindications to respiratory function tests: Recent eye or throat surgery, recent myocardial infarction or pulmonary embolism, poorly controlled high blood pressure, recent pneumothorax.
- Pregnant or breastfeeding women, patients under guardianship or curatorship, deprived of liberty
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Non-exposed
Subject with low exposure to silica <0.1 mg/m3 in the course of their professional activity
|
Spirometry, plethysmography, FeNO test
25mL peripheral blood will be collected
|
|
Other: Exposed
Subject with moderate or high exposure to silica (>= 0.1 mg/m3) in the course of their professional activity
|
Spirometry, plethysmography, FeNO test
25mL peripheral blood will be collected
Non-injected thoracic CT scan
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Prevalence ratio of AACD146 between the exposed and non-exposed groups.
Time Frame: At enrollment
|
At enrollment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
AACD146 prevalence in patients with interstitial or neoplastic lung disease.
Time Frame: At enrollment
|
At enrollment
|
|
AACD146 Prevalence by type of interstitial lung disease
Time Frame: At enrollment
|
At enrollment
|
|
AACD146 Prevalence by type of histological type of lung cancer.
Time Frame: At enrollment
|
At enrollment
|
|
Correlation between AACD146 and exposure duration and dose to silica
Time Frame: At enrollment
|
At enrollment
|
|
Correlation between AACD146 and soluble CD146
Time Frame: At enrollment
|
At enrollment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2024-A02509-38
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.